Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Peptides for cognitive decline and nootropic use: what the evidence shows

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

At a glance

Semax, selank, dihexa, cerebrolysin, and related compounds are marketed for cognition. Cerebrolysin has small clinical trials in stroke and dementia, mostly outside the United States. Semax and selank have Russian clinical literature but no indexed US or EU randomized trials. Dihexa and P21 are animal-only.

Evidence: Strongest: Human RCT evidence5 peptides gradedVerified: Verified Nov 1, 2026

Do peptides help with cognitive decline and nootropic use?

5 peptides are graded for cognitive decline and nootropic use on this page. The strongest grade is human RCT evidence, for cerebrolysin. Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.

What is the standard of care for cognitive decline and nootropic use?

Evaluation for reversible causes; management of vascular risk factors, sleep, hearing, and depression; cholinesterase inhibitors and memantine for Alzheimer disease; anti-amyloid antibodies in selected early cases.

Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.

Which peptides have been studied for cognitive decline and nootropic use?

Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.

Peptides studied for Cognitive decline and nootropic use with evidence grades
PeptideEvidence for this useNote
CerebrolysinEvidence: Human RCT evidenceSmall trials in stroke and dementia with mixed results; not FDA approved. [1]
SemaxEvidence: Human observational evidenceApproved in Russia; Russian clinical reports; no indexed RCT; FDA's drug center recommended against 503A listing and the advisory committee voted in favor (HHS policy, Appendix B); HHS's October 2026 draft policy, which is not an approval, covers conditional compounding of the single-ingredient product. [1] [5]
SelankEvidence: Human observational evidenceApproved in Russia for anxiety; its two randomized trials were unblinded, had no placebo group, and enrolled patients with anxiety disorders, so they do not raise the grade for cognition; one comparative anxiety study reported mild nootropic effects. [1]
NoopeptEvidence: Human observational evidenceNot a peptide in the strict sense (dipeptide derived); Russian clinical reports only. [3]
DihexaEvidence: Animal-only evidenceRodent studies only; no human safety data. [1]

Head-to-head comparisons

Cost and access

Price ranges, lawful channels, and insurance notes for peptides graded here. State rules are in the legal guides by state.

Frequently asked questions

Which peptide has the strongest evidence for cognitive decline and nootropic use?

Cerebrolysin has the strongest evidence among the peptides graded here, at human RCT evidence. Small trials in stroke and dementia with mixed results; not FDA approved. [1]

Is any peptide FDA approved for cognitive decline and nootropic use?

No. None of the peptides graded for cognitive decline and nootropic use is an FDA approved drug, so any use is outside an approved label and depends on the compounding and research status shown on each peptide page. [4]

Has any peptide been tested in a randomized trial for cognitive decline and nootropic use?

Yes, for cerebrolysin. Check each note for the population and endpoints: a randomized trial in a related group or on a surrogate marker is weaker than one on the outcome you care about. [1]

From the blog

Sources

  1. [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  2. [2]PubMed search: cerebrolysin randomized controlled trial2026
  3. [3]Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic originPubMed 19234797, 2009
  4. [4]Drugs@FDA: FDA-approved drugs databaseFDA
  5. [5]HHS: draft enforcement discretion policy for 503A compounding using certain peptide bulk drug substances, with Appendix A (covered peptides) and Appendix B (identity, routes, and committee history), October 28, 20262026